Blockchain Registration Transaction Record

AXIM Biotechnologies Engages Ocular Innovator Dr. Alan Touch as Regulatory Advisor

AXIM Biotechnologies hires Dr. Alan Touch, a global regulatory leader and ocular diagnostic innovator, to enhance regulatory strategy and accelerate commercialization of its TearScan® platform.

This news matters because it highlights a strategic move by AXIM Biotechnologies to bolster its regulatory and clinical capabilities at a critical juncture, potentially accelerating the development and approval of innovative diagnostic tools for ocular diseases like dry eye disease. With Dr. Touch's expertise, AXIM can navigate complex global regulatory landscapes more efficiently, reducing time-to-market for its TearScan® platform and other products. For patients and healthcare providers, this could lead to faster access to accurate, point-of-care diagnostics that improve treatment outcomes and enhance diagnostic confidence in managing conditions affecting millions worldwide. In the competitive biotechnology sector, such partnerships often signal a company's commitment to quality and innovation, which can drive investor confidence and industry advancements.